Optimark and Peripheral coldness - a phase IV clinical study of FDA data

Summary:

Peripheral coldness is reported as a side effect among people who take Optimark (gadoversetamide), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Magnevist, and have High blood pressure.

The phase IV clinical study analyzes which people have Peripheral coldness when taking Optimark. It is created by eHealthMe based on reports of 3,054 people who have side effects when taking Optimark from the FDA, and is updated regularly.

What is Optimark?

Optimark has active ingredients of gadoversetamide. eHealthMe is studying from 3,055 Optimark users. Check the latest studies of Optimark.

What is Peripheral coldness?

Peripheral coldness is found to be associated with 1,075 drugs and 1,154 conditions by eHealthMe. Check the latest studies of Peripheral coldness.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

3,054 people reported to have side effects when taking Optimark.
Among them, 25 people (0.82%) have Peripheral coldness.

Could Optimark cause Peripheral coldness?

Among these 25 people:

How long have people been on Optimark when they have Peripheral coldness? *

What is the gender of people who have Peripheral coldness when taking Optimark? *

female: 76 %
male: 24 %

What is the age of people who have Peripheral coldness when taking Optimark? *

What are other drugs people take besides Optimark? *

What are other side effects people have besides Peripheral coldness? *

Rashes (redness): 25 people, 100.00%
Pain: 24 people, 96.00%
Scar: 22 people, 88.00%
Pain In Extremity: 22 people, 88.00%
Skin Exfoliation (removal of the oldest dead skin cells): 22 people, 88.00%
Oedema Peripheral (superficial swelling): 22 people, 88.00%
Skin Induration (an abnormally hard spot or area on the skin): 22 people, 88.00%
Nephrogenic Systemic Fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease): 22 people, 88.00%
Skin Fissures (a crack in the skin): 17 people, 68.00%
Joint Stiffness: 17 people, 68.00%

What are the existing conditions these people have? *

High Blood Pressure: 9 people, 36.00%
Nuclear Magnetic Resonance Imaging Brain: 6 people, 24.00%
Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 6 people, 24.00%
Platelet Count Increased: 5 people, 20.00%
Venous Pressure Increased: 4 people, 16.00%
Peripheral Arterial Occlusive Disease (reproducible ischemic muscle pain): 3 people, 12.00%
Nuclear Magnetic Resonance Imaging Abdominal: 1 person, 4.00%
Computerised Tomogram Abdomen: 1 person, 4.00%
Brain Neoplasm (tumour of brain): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Optimark and have Peripheral coldness?

- Check whether Peripheral coldness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Optimark:

Optimark (3,055 reports)

Browse all side effects of Optimark:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Peripheral coldness:

Peripheral coldness (1,075 drugs)

Browse all the conditions that are associated with Peripheral coldness:

Peripheral coldness (1,154 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gadoversetamide (the active ingredients of Optimark) and Optimark (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.